Introduction. Liver diseases with all the variety of clinical manifestations have common pathogenetic links at the cellular level. The group of hepatoprotective agents is represented by drugs that exhibit versatile mechanisms for protecting liver cells from the effects of damaging factors, the main of which are membrane-stabilizing, antioxidant, regenerative, detoxifying, choleretic and anti-inflammatory effects. The high therapeutic and hepatoprotective effectiveness of modern drugs is largely due to their metabolic effects, as well as their ability to bind free radicals and reactive oxygen species in the cell.Text. The purpose of this work is to form an analytical review of the literature on the assortment and concepts of improving the dosage forms of hepatoprotective agents. According to the analysis and systematization of modern publications devoted to the use of hepatoprotectors in the treatment of liver diseases, it is shown that it is necessary to develop new formulations and combinations of biologically active substances with the manifestation of versatile mechanisms of hepatoprotection, as well as to improve the composition and manufacturing technologies of existing traditional therapies. One of the current trends is the use of new substances in the development of traditional and innovative dosage forms. The search for biologically active molecules with antioxidant, antiradical and membrane-stabilizing activity that can be considered as effective hepatoprotectors continues. An integral task of pharmaceutical development is the creation of bioavailable drugs that have a prolonged effect and minimal side effects. A promising direction in pharmaceutical technology is the development of innovative drugs for the directed transport of biologically active molecules to the affected organ.Conclusion. As a result of the analysis of modern data, priority directions for the development and improvement of existing formulations based on modern approaches to the production of innovative dosage forms are identified. The relevance of improving the dosage forms of hepatoprotectors presented on the pharmaceutical market is shown. Of particular interest is the development of innovative targeted delivery systems with effective and safe hepatoprotectors in various combinations, including those based on cinnamic acid derivatives.

One of the urgent tasks in the process of drug development is to obtain stable pharmaceutical products in the process of storage and use. To establish the expiration date, it is necessary to determine the time during which the developed drug is able to maintain stability and meet all the requirements stated in the regulatory documentation. The aim of the study was to study the stability of laboratory samples of wound healing gel with cycvalone during long-term storage in natural conditions. The developed composition of the wound healing gel includes the antioxidant agent cycvalone, which has a pronounced manifestation of antioxidant and anti-radical activity, as well as has a wound healing, immunotropic and anti-inflammatory effect. Carbomer (Carbopol-940), potassium hydroxide solution and purified water were used as excipients. Gel samples were stored in the primary packaging at room temperature in a place protected from light. The stability of the dosage form was studied according to the following parameters: description, pH of water extraction, authenticity, colloidal and thermal stability, quantitative determination, rheological parameters in accordance with the developed methods. The measurement was performed on 6 series of dosage forms: after preparation, after 6, 12, 18 and 24 months of storage in vivo. The results of determining the quality indicators of the wound healing gel with an antioxidant agent (cycvalone) indicate a rational selection of active and auxiliary substances and their concentration, the choice of a rational technology and the absence of interaction between the components of the developed dosage form. Based on the conducted studies, it is proved that the wound healing gel with cycvalone remains stable during storage at a temperature of 15 to 25 ˚С for 24 months.

One of the promising areas of the pharmaceutical industry is the development of local drug delivery systems consisting of a biocompatible matrix and a drug. Such local delivery systems include medicinal films. Ensuring pharmacological action, accuracy of dosing, strong fixation to damaged tissues of the mucous membrane, prolongation of action are the undoubted advantages of medicinal films in comparison with traditional means of treating wound processes. The development of the technology of the drug film containing in its composition the drug cycvalone, which has a wide range of biological activity-antioxidant, anti-inflammatory, antibacterial and others - is an urgent task of pharmacy. As a result of the conducted research, the technology of a drug film with cycvalone in the form of an inclusion complex with β-cyclodextrin based on a matrix of a biodegradable polymer of sodium alginate was developed. It should be noted the availability, safety and pharmacological effectiveness of medicinal substances used in the technology of the dosage form. The inclusion of cyclodextrin in the composition of the film is due to the solubilization of the active substance molecule and an increase in the bioavailability of cycvalone during application therapy. Introduction of cycvalone in the form of complex inclusion also has a positive effect on the uniformity of distribution of the drug in the matrix and, consequently, determines the accuracy of drug dosing. After the release of the active substance, cyclodextrin is able to show detoxifying properties in the wound. The use of a modern biodegradable material as a film-forming agent provides a prolonged action of active substances, high bioavailability and enhanced therapeutic properties of the composition. The values of quality indicators of medicinal films confirming the rational selection of the composition and the optimal technology of the dosage form were experimentally established.

Salt Lake Elton is one of the most valuable natural objects of the Volgograd region. Therapeutic muds are characterized by a wide spectrum of pharmacological activity, a positive effect on cellular humoral nonspecific immunity in terms of initiating prooxidant processes contribute to the restoration of balanced functioning of the system of lipid peroxidation and the antioxidant system. However, the use of native therapeutic mud in therapy has a number of contraindications and limitations. Native therapeutic mud is not stable, biologically active substances of therapeutic mud are destroyed under the influence of environmental factors, losing their properties during transportation and storage. The development of technology of dosage forms based on extracts from native therapeutic mud that do not have the disadvantages inherent in native mud, convenient for use, transportation and storage is an urgent task of pharmacy. So, the technology allowing to receive an oil solution of the lipid complex "Elton"is patented. The product" Elton " has an analgesic, anti-inflammatory, wound healing, keratoplastic, antioxidant, membrane-stabilizing effect. The aim of the study was to develop a technology of biodegradable drug film containing an oil solution of the lipid complex "Elton". The oil solution has a low adhesive ability, drains from the application site, which negatively affects the effectiveness of treatment. The development of the drug film technology will eliminate the listed disadvantages of the oil solution of the lipid complex "Elton", will provide a prolonged and local action at the application site. In the development of medicinal films, we used gelatin as a base-forming component, which has a high ability to gel, physiological indifference, good adhesive properties, hemostatic and wound-healing effect.